Precision Net Receivables vs Capital Surpluse Analysis

DTIL Stock

USD 6.50 0.68 9.47%

Precision BioSciences financial indicator trend analysis is much more than just breaking down Precision BioSciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Precision BioSciences is a good investment. Please check the relationship between Precision BioSciences Net Receivables and its Capital Surpluse accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.

Net Receivables vs Capital Surpluse

Net Receivables vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Precision BioSciences Net Receivables account and Capital Surpluse. At this time, the significance of the direction appears to have strong relationship.

The correlation between Precision BioSciences' Net Receivables and Capital Surpluse is 0.73. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Precision BioSciences, assuming nothing else is changed. The correlation between historical values of Precision BioSciences' Net Receivables and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Precision BioSciences are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Net Receivables i.e., Precision BioSciences' Net Receivables and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.73

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Receivables

Capital Surpluse

Most indicators from Precision BioSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Precision BioSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.At this time, Precision BioSciences' Sales General And Administrative To Revenue is quite stable compared to the past year. Enterprise Value Over EBITDA is expected to rise to 1.42 this year, although the value of Selling General Administrative will most likely fall to about 29 M.

	2021	2022	2023	2024 (projected)
Gross Profit	115.5M	16.1M	40.5M	33.4M
Total Revenue	115.5M	25.1M	48.7M	35.8M

Gross Profit Total Revenue

Precision BioSciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Capital Surpluse	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity
Total Assets		0.28	0.81	0.9	-0.55	0.93	-0.76	0.03	0.95	0.61	0.95	0.28	-0.68	0.83	0.61	0.98	0.78	0.78	0.8	0.79	-0.94	0.9	0.67	0.04	0.65	0.88
Other Current Liab	0.28		0.56	0.02	0.02	0.13	-0.53	-0.29	0.28	0.49	0.28	0.34	0.15	0.46	0.67	0.3	0.07	0.02	0.02	0.45	-0.04	0.24	0.49	0.36	0.27	0.49
Total Current Liabilities	0.81	0.56		0.56	-0.54	0.69	-0.94	0.04	0.68	0.67	0.68	0.59	-0.69	0.92	0.82	0.76	0.57	0.73	0.66	0.88	-0.63	0.81	0.7	0.15	0.6	0.97
Total Stockholder Equity	0.9	0.02	0.56		-0.57	0.94	-0.47	0.06	0.82	0.53	0.82	0.06	-0.62	0.58	0.22	0.86	0.86	0.8	0.84	0.56	-0.93	0.85	0.45	-0.31	0.54	0.67
Other Liab	-0.55	0.02	-0.54	-0.57		-0.64	0.6	-0.11	-0.3	-0.36	-0.3	-0.67	0.7	-0.65	-0.05	-0.4	-0.53	-0.9	-0.9	-0.5	0.39	-0.8	-0.04	0.6	-0.43	-0.6
Net Tangible Assets	0.93	0.13	0.69	0.94	-0.64		-0.68	0.28	0.83	0.44	0.83	0.34	-0.69	0.77	0.36	0.9	0.76	0.85	0.83	0.57	-0.88	0.87	0.38	-0.25	0.58	0.82
Retained Earnings	-0.76	-0.53	-0.94	-0.47	0.6	-0.68		-0.22	-0.63	-0.5	-0.63	-0.75	0.69	-0.99	-0.78	-0.71	-0.44	-0.69	-0.61	-0.75	0.53	-0.77	-0.52	-0.17	-0.65	-0.96
Accounts Payable	0.03	-0.29	0.04	0.06	-0.11	0.28	-0.22		-0.02	-0.53	-0.02	0.39	-0.32	0.25	-0.09	0.05	-0.13	0.19	-0.02	-0.36	-0.04	-0.05	-0.47	-0.15	0.07	0.19
Cash	0.95	0.28	0.68	0.82	-0.3	0.83	-0.63	-0.02		0.48	1.0	0.1	-0.47	0.69	0.63	0.99	0.63	0.57	0.61	0.71	-0.93	0.72	0.68	0.24	0.47	0.74
Other Assets	0.61	0.49	0.67	0.53	-0.36	0.44	-0.5	-0.53	0.48		0.48	0.02	-0.46	0.48	0.52	0.52	0.76	0.49	0.56	0.79	-0.53	0.74	0.83	0.05	0.68	0.61
Cash And Short Term Investments	0.95	0.28	0.68	0.82	-0.3	0.83	-0.63	-0.02	1.0	0.48		0.1	-0.47	0.69	0.63	0.99	0.63	0.57	0.61	0.71	-0.93	0.72	0.68	0.24	0.47	0.74
Net Receivables	0.28	0.34	0.59	0.06	-0.67	0.34	-0.75	0.39	0.1	0.02	0.1		-0.43	0.73	0.34	0.2	0.0	0.54	0.43	0.33	0.01	0.42	-0.1	-0.17	0.26	0.6
Common Stock Shares Outstanding	-0.68	0.15	-0.69	-0.62	0.7	-0.69	0.69	-0.32	-0.47	-0.46	-0.47	-0.43		-0.72	-0.36	-0.57	-0.66	-0.83	-0.76	-0.6	0.65	-0.79	-0.38	0.18	-0.65	-0.75
Capital Surpluse	0.83	0.46	0.92	0.58	-0.65	0.77	-0.99	0.25	0.69	0.48	0.69	0.73	-0.72		0.73	0.78	0.5	0.75	0.69	0.74	-0.61	0.82	0.49	0.1	0.66	0.96
Total Liab	0.61	0.67	0.82	0.22	-0.05	0.36	-0.78	-0.09	0.63	0.52	0.63	0.34	-0.36	0.73		0.64	0.25	0.24	0.2	0.77	-0.46	0.45	0.8	0.68	0.46	0.74
Total Current Assets	0.98	0.3	0.76	0.86	-0.4	0.9	-0.71	0.05	0.99	0.52	0.99	0.2	-0.57	0.78	0.64		0.69	0.67	0.68	0.74	-0.94	0.8	0.66	0.16	0.56	0.82
Intangible Assets	0.78	0.07	0.57	0.86	-0.53	0.76	-0.44	-0.13	0.63	0.76	0.63	0.0	-0.66	0.5	0.25	0.69		0.74	0.79	0.63	-0.79	0.85	0.59	-0.26	0.77	0.63
Property Plant Equipment	0.78	0.02	0.73	0.8	-0.9	0.85	-0.69	0.19	0.57	0.49	0.57	0.54	-0.83	0.75	0.24	0.67	0.74		0.97	0.65	-0.69	0.91	0.29	-0.48	0.53	0.79
Property Plant And Equipment Net	0.8	0.02	0.66	0.84	-0.9	0.83	-0.61	-0.02	0.61	0.56	0.61	0.43	-0.76	0.69	0.2	0.68	0.79	0.97		0.69	-0.71	0.94	0.35	-0.48	0.54	0.72
Current Deferred Revenue	0.79	0.45	0.88	0.56	-0.5	0.57	-0.75	-0.36	0.71	0.79	0.71	0.33	-0.6	0.74	0.77	0.74	0.63	0.65	0.69		-0.67	0.8	0.85	0.22	0.53	0.79
Net Debt	-0.94	-0.04	-0.63	-0.93	0.39	-0.88	0.53	-0.04	-0.93	-0.53	-0.93	0.01	0.65	-0.61	-0.46	-0.94	-0.79	-0.69	-0.71	-0.67		-0.78	-0.64	-0.03	-0.53	-0.71
Non Current Assets Total	0.9	0.24	0.81	0.85	-0.8	0.87	-0.77	-0.05	0.72	0.74	0.72	0.42	-0.79	0.82	0.45	0.8	0.85	0.91	0.94	0.8	-0.78		0.57	-0.23	0.74	0.86
Non Currrent Assets Other	0.67	0.49	0.7	0.45	-0.04	0.38	-0.52	-0.47	0.68	0.83	0.68	-0.1	-0.38	0.49	0.8	0.66	0.59	0.29	0.35	0.85	-0.64	0.57		0.51	0.53	0.6
Non Current Liabilities Total	0.04	0.36	0.15	-0.31	0.6	-0.25	-0.17	-0.15	0.24	0.05	0.24	-0.17	0.18	0.1	0.68	0.16	-0.26	-0.48	-0.48	0.22	-0.03	-0.23	0.51		0.06	0.06
Other Current Assets	0.65	0.27	0.6	0.54	-0.43	0.58	-0.65	0.07	0.47	0.68	0.47	0.26	-0.65	0.66	0.46	0.56	0.77	0.53	0.54	0.53	-0.53	0.74	0.53	0.06		0.69
Other Stockholder Equity	0.88	0.49	0.97	0.67	-0.6	0.82	-0.96	0.19	0.74	0.61	0.74	0.6	-0.75	0.96	0.74	0.82	0.63	0.79	0.72	0.79	-0.71	0.86	0.6	0.06	0.69

Click cells to compare fundamentals

Precision BioSciences Account Relationship Matchups

Precision BioSciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	235.2M	150.2M	211.5M	238.2M	159.8M	179.4M
Other Current Liab	1.6M	7.9M	9.9M	11.1M	11.4M	6.7M
Total Current Liabilities	26.9M	42.8M	36.0M	59.7M	50.0M	34.0M
Total Stockholder Equity	138.3M	44.4M	91.2M	60.4M	18.9M	17.9M
Other Liab	70.0M	54.3M	77.1M	93.1M	83.8M	64.4M
Net Tangible Assets	136.9M	43.1M	89.1M	59.1M	67.9M	52.7M
Retained Earnings	(177.1M)	(286.1M)	(316.7M)	(428.3M)	(489.6M)	(465.1M)
Accounts Payable	2.0M	792K	1.1M	653K	3.0M	1.8M
Cash	180.9M	89.8M	143.7M	189.6M	116.7M	134.8M
Other Assets	558K	8.1M	11.5M	9.8M	1.0	0.95
Cash And Short Term Investments	180.9M	89.8M	143.7M	189.6M	116.7M	134.8M
Net Receivables	965K	10M	488K	720K	12.8M	13.4M
Common Stock Shares Outstanding	1.4M	1.7M	2.0M	2.9M	3.8M	3.1M
Capital Surpluse	316.3M	331.5M	408.8M	489.7M	563.2M	591.3M
Total Liab	96.9M	105.7M	120.3M	177.7M	140.9M	129.6M
Total Current Assets	193.7M	105.6M	161.8M	199.1M	136.4M	147.2M
Intangible Assets	1.4M	1.4M	2.0M	1.3M	400K	380K
Property Plant Equipment	39.6M	41.5M	25.2M	20.2M	23.2M	25.0M
Property Plant And Equipment Net	39.6M	41.5M	29.3M	23.2M	14.6M	27.9M
Current Deferred Revenue	16.5M	30.2M	21.2M	46.2M	12.0M	22.1M
Net Debt	(180.9M)	(79.3M)	(134.6M)	(162.5M)	(85.4M)	(89.7M)
Non Current Assets Total	41.6M	44.6M	49.7M	39.1M	23.4M	36.1M
Non Currrent Assets Other	558K	1.7M	4.6M	9.8M	225.0K	213.7K
Liabilities And Stockholders Equity	235.2M	150.2M	211.5M	238.2M	159.8M	189.5M
Non Current Liabilities Total	70.0M	62.9M	84.4M	118.1M	90.9M	94.4M
Other Current Assets	2.3M	5.8M	17.6M	8.8M	6.9M	8.5M
Other Stockholder Equity	315.4M	330.5M	407.8M	488.7M	508.5M	345.3M
Net Invested Capital	138.3M	44.4M	93.6M	82.7M	41.3M	65.0M
Property Plant And Equipment Gross	39.6M	41.5M	53.2M	54.3M	40.1M	40.5M
Net Working Capital	166.7M	62.7M	125.8M	139.4M	86.4M	115.9M
Short Term Debt	6.8M	3.9M	3.6M	1.7M	23.5M	24.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Precision BioSciences is a strong investment it is important to analyze Precision BioSciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Precision BioSciences' future performance. For an informed investment choice regarding Precision Stock, refer to the following important reports:

How To Invest In Precision

Details

Is Precision Stock a good investment?

Details

What is Precision BioSciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.4

Revenue Per Share

12.872

Quarterly Revenue Growth

(0.96)

Return On Assets

(0.06)

Return On Equity

0.2444

The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Precision Net Receivables vs Capital Surpluse Analysis

Net Receivables vs Capital Surpluse

Net Receivables vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Net Receivables

Capital Surpluse

Precision BioSciences fundamental ratios Correlations

Precision BioSciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Precision BioSciences fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Current Assets	+ 0.98	Total Assets
Other Stockholder Equity	+ 0.97	Total Current Liabilities
Property Plant And Equipment Net	+ 0.97	Property Plant Equipment

Capital Surpluse	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Net Debt	- 0.94	Total Current Assets
Retained Earnings	- 0.94	Total Current Liabilities
Net Debt	- 0.94	Total Assets
Net Debt	- 0.93	Cash And Short Term Investments